CyclinD1 and p57kip2 as biomarkers in differentiation, metastasis and prognosis of gastric cardia adenocarcinoma
Metrics: PDF 1265 views | HTML 2170 views | ?
Yi Ru1,*, Xiao-Jie Chen2,*, Zhi-Wei Zhao1, Peng-Fei Zhang1, Shuai-Hao Feng1, Qiang Gao1, She-Gan Gao1,2,3,4 and Xiao-Shan Feng1,3,4
1The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology , Luoyang, Henan 471003, China
2Medical College, Henan University of Science and Technology , Luoyang, Henan 471003, China
3Henan Key Laboratory of Cancer Epigenetics, Henan University of Science and Technology , Luoyang, Henan 471003, China
4Cancer Institute, Henan University of Science and Technology , Luoyang, Henan 471003, China
*These authors contributed equally to this work and co-first authors
Xiao-Shan Feng, email: [email protected]
Keywords: gastric cardia adenocarcinoma, p57kip2, cyclinD1, clinical stage, different degrees of differentiation
Received: February 21, 2017 Accepted: April 19, 2017 Published: May 19, 2017
Objective: This study aims to investigate the expression and significance of p57kip2 and cyclinD1 in gastric cardia adenocarcinoma (GCA). p57kip2 is a negative regulator in the cell cycle. On the contrary, cyclinD1 is a positive regulator of cell cycle progression. Methods: Thirty-two cases of GCA tissues and adjacent non-cancerous tissues were collected for this study. Immunohistochemistry and fluorescence qualitative PCR was used to determine the level of p57kip2 and cyclinD1 in GCA and its adjacent non-cancerous tissues. Furthermore, the correlation between the mRNA/protein and GCA clinical pathologic parameters were analyzed, and the ralationship of p57kip2 and cyclinD1 in GCA were also evaluated. Results: The expression of p57kip2 significantly lower in GCA (P = 0.036), and there was a significant correlation in the different degrees of differentiation (P < 0.05). Furthermore, median survival time was 41 months for patients with high mRNA expression of p57kip2. This was longer compared to patients with low mRNA expression of P57kip2 (37 months, X2 = 4.788, P = 0.029).The expression of cyclinD1 was significantly higher in GCA(P = 0.002), and was significant correlated to clinical stage(P<0.05). Median survival time was 34 months in patients with high mRNA expression of cyclinD1, which was shorter than in patients with low expression of cyclinD1 mRNA (41 months, X2 = 4.071, P = 0.044). The protein expression of p57kip2 was not correlated to the protein expression of cyclinD1 (P = 0.55). Conclusion: The expression of p57kip2 and cyclinD1 are likely to suppress or promote the tumorigenesis and progression of GCA.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.